title: Development of acid-resistant alginate/trimethyl chitosan nanoparticles containing cationic β-cyclodextrin polymers for insulin oral delivery.
abstract: In this study, the use of trimethylchitosan (TMC), by higher solubility in comparison with chitosan, in alginate/chitosan nanoparticles containing cationic β-cyclodextrin polymers (CPβCDs) has been studied, with the aim of increasing insulin uptake by nanoparticles. Firstly, TMCs were synthesized by iodomethane, and CPβCDs were synthesized within a one-step polycondensation reaction using choline chloride (CC) and epichlorohydrine (EP). Insulin-CβCDPs complex was prepared by mixing 1:1 portion of insulin and CPβCDs solutions. Then, nanoparticles prepared in a three-step procedure based on the iono-tropic pregelation method. Nanoparticles screened using experimental design and Placket Burman methodology to obtain minimum size and polydispercity index (pdI) and the highest entrapment efficiency (EE). CPβCDs and TMC solution concentration and pH and alginate and calcium chloride solution concentrations are found as the significant parameters on size, PdI, and EE. The nanoparticles with proper physicochemical properties were obtained; the size, PdI, and EE% of optimized nanoparticles were reported as 150.82 ± 21 nm, 0.362 ± 0.036, and 93.2% ± 4.1, respectively. The cumulative insulin release in intestinal condition achieved was 50.2% during 6 h. By SEM imaging, separate, spherical, and nonaggregated nanoparticles were found. In the cytotoxicity studies on Caco-2 cell culture, no significant cytotoxicity was observed in 5 h of incubation, but after 24 h of incubation, viability was decreased to 50% in 0.5 mμ of TMC concentration. Permeability studies across Caco-2 cells had been carried out, and permeability achieved in 240 min was 8.41 ± 0.39%, which shows noticeable increase in comparison with chitosan nanoparticles. Thus, according to the results, the optimized nanoparticles can be used as a new insulin oral delivery system.
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Enghelab Ave., Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Mansourpour
authors.forename: Reza
authors.initials: R
authors.lastname: Mahjub
authors.forename: Mohsen
authors.initials: M
authors.lastname: Amini
authors.forename: Seyed Naser
authors.initials: SN
authors.lastname: Ostad
authors.forename: Elnaz Sadat
authors.initials: ES
authors.lastname: Shamsa
authors.forename: Morteza
authors.initials: M
authors.lastname: Rafiee-Tehrani
authors.forename: Farid Abedin
authors.initials: FA
authors.lastname: Dorkoosh
mesh_terms: D000143:Acids / Q000737:chemistry*; D000284:Administration, Oral; D000464:Alginates; D018938:Caco-2 Cells; D048271:Chitosan / Q000737:chemistry*; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D006801:Humans; D066298:In Vitro Techniques; D007328:Insulin / Q000008:administration & dosage*; D008855:Microscopy, Electron, Scanning; D011108:Polymers / Q000737:chemistry*; D066244:Proton Magnetic Resonance Spectroscopy; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D000143:Acids; D000464:Alginates; D006603:Hexuronic Acids; D007328:Insulin; D011108:Polymers; D047392:beta-Cyclodextrins; D020723:Glucuronic Acid; D048271:Chitosan; C031215:betadex